Literature DB >> 15694409

Alternative bisphosphonate targets and mechanisms of action.

Jack F Bukowski1, Christopher C Dascher, Hiranmoy Das.   

Abstract

As the number of bisphosphonates continues to increase, they have found widespread use in an increasing number of clinical conditions. Ongoing examination of their targets and mechanisms of action has revealed that this surprisingly diverse class of drugs has effects beyond those first described for osteoclasts. These additional targets include osteoblasts, osteocytes, angiogenesis, and gammadelta T lymphocytes of the human immune system. The immune system effects are specifically targeted to gammadelta T cells and are reminiscent of the effects seen after ingestion of tea beverage. BP effects on such alternate targets may explain not only their antiresorptive effect, but also their effect on bone quality, tumors, and microbes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15694409     DOI: 10.1016/j.bbrc.2004.11.075

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  18 in total

1.  Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings.

Authors:  Sebastian Hoefert; Inge Schmitz; Andrea Tannapfel; Harald Eufinger
Journal:  Clin Oral Investig       Date:  2009-06-18       Impact factor: 3.573

2.  Vγ9 Vδ2 T lymphocytes activation as a novel approach to test efficacy of different bisphosphonates.

Authors:  Giovam Battista Rini; Delia Sprini; Silvia Migliaccio; Stefania Basili; Rocky Strollo; Francesco Dieli; Nicola Napoli
Journal:  Endocrine       Date:  2014-08-06       Impact factor: 3.633

3.  Treatment of skeletal Erdheim-Chester disease with zoledronic acid: case report and proposed mechanisms of action.

Authors:  Thitinan Srikulmontree; H Davis Massey; W Neal Roberts
Journal:  Rheumatol Int       Date:  2006-08-25       Impact factor: 2.631

Review 4.  Bisphosphonate treatment and radiotherapy in metastatic breast cancer.

Authors:  A Ugur Ural; Ferit Avcu; Yusuf Baran
Journal:  Med Oncol       Date:  2008-01-17       Impact factor: 3.064

Review 5.  [Bisphosphonate-associated osteonecrosis of the jaw].

Authors:  Maria-Theresa Krauth; Alexander Fügl; Reinhard Gruber
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

6.  A novel soft-tissue in vitro model for bisphosphonate-associated osteonecrosis.

Authors:  Ma Scheper; R Chaisuparat; Kj Cullen; Tf Meiller
Journal:  Fibrogenesis Tissue Repair       Date:  2010-04-01

7.  Anti-tumor cytotoxicity of gammadelta T cells expanded from peripheral blood cells of patients with myeloma and lymphoma.

Authors:  Anri Saitoh; Miwako Narita; Norihiro Watanabe; Nozomi Tochiki; Noriyuki Satoh; Jun Takizawa; Tatsuo Furukawa; Ken Toba; Yoshifusa Aizawa; Shohji Shinada; Masuhiro Takahashi
Journal:  Med Oncol       Date:  2007-09-11       Impact factor: 3.064

8.  Vγ9Vδ2 T lymphocytes activation in osteoporotic patients treated with bisphosphonates.

Authors:  Delia Sprini; Laura Di Stefano; Giovam Battista Rini; Luisella Cianferotti; Nicola Napoli
Journal:  Clin Cases Miner Bone Metab       Date:  2014-05

Review 9.  Optimizing dosing frequencies for bisphosphonates in the management of postmenopausal osteoporosis: patient considerations.

Authors:  John Sunyecz
Journal:  Clin Interv Aging       Date:  2008       Impact factor: 4.458

10.  Long Term Cyclic Pamidronate Reduces Bone Growth by Inhibiting Osteoclast Mediated Cartilage-to-Bone Turnover in the Mouse.

Authors:  K D Evans; L E Sheppard; D I Grossman; S H Rao; R B Martin; A M Oberbauer
Journal:  Open Orthop J       Date:  2008-07-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.